1. The anticonvulsant, local anesthetic and hemodynamic properties of some chiral aminobutanol derivatives of xanthone
Magdalena Jastrzebska-Wiesek, Ryszard Czarnecki, Henryk Marona Acta Pol Pharm. 2008 Sep-Oct;65(5):591-600.
In the present study, several pharmacological tests in animals were carried out to assess potential anticonvulsant, local anesthetic and hemodynamic activity of novel 2- and 4-substituted aminobutanol chiral derivatives of xanthone (hydrochlorides of: (R,S)-2-[(7-chloro)-2-xanthonemethyl)]-N-methylaminobutan-1-ol (MH-2(R,S)), (R,S)-2-(4-xanthonemethyl)-aminobutan-1-ol (MH-20(R,S)) and (R,S)-2-[(6-methoxy)-2-xanthonemethyl]-aminobutan-1-ol (MH-26(R,S)) and their pure enantiomers R and S). The obtained results provided evidence that the most interesting anticonvulsant (in maximal electroshock-test) activity was shown by compound MH-2(R), which in dose 100 mg/kg p.o., protected the mice against tonic cramp of extensors similarly as phenytoin. Moreover, this compound, in concentrations from 0.25 to 1%, also possessed high local anesthetic activity (in infiltration anesthesia), comparable to the reference compound, mepivacaine. All examined compounds suppressed the spontaneous locomotor activity in mice, especially compound MH-2(R,S) and MH-20(R,S), and their enantiomers. The impairment of motor coordination (in chimney test) for applied doses was not observed. Furthermore, compound MH-20(S) at dose corresponding to 1/10 LD50 displayed an interesting hemodynamic activity and significantly decreased systolic and diastolic blood pressure in rats. All examined compounds showed chronotropic negative effect in anesthetized rats ECG record. The most reducing heart frequency was observed for enantiomers S of aminobutanol derivatives of xanthone, especially MH-2(S). The LD50 values of the investigated compounds were comparable with LD50 value of the reference compound in local anesthesia tests--mepivacaine. These studies demonstrated different strength of enantiomers and racemic mixture in carried out tests, where the R enantiomers presented rather central and local anesthetic properties, whereas S enatiomers influenced the hemodynamic activity.
2. Endothelial S1P1 Signaling Counteracts Infarct Expansion in Ischemic Stroke
Anja Nitzsche, Marine Poittevin, Ammar Benarab, et al. Circ Res. 2021 Feb 5;128(3):363-382.doi: 10.1161/CIRCRESAHA.120.316711.Epub 2020 Dec 2.
Rationale:Cerebrovascular function is critical for brain health, and endogenous vascular protective pathways may provide therapeutic targets for neurological disorders. S1P (Sphingosine 1-phosphate) signaling coordinates vascular functions in other organs, and S1P1 (S1P receptor-1) modulators including fingolimod show promise for the treatment of ischemic and hemorrhagic stroke. However, S1P1 also coordinates lymphocyte trafficking, and lymphocytes are currently viewed as the principal therapeutic target for S1P1 modulation in stroke. Objective:To address roles and mechanisms of engagement of endothelial cell S1P1 in the naive and ischemic brain and its potential as a target for cerebrovascular therapy.Methods and results:Using spatial modulation of S1P provision and signaling, we demonstrate a critical vascular protective role for endothelial S1P1 in the mouse brain. With an S1P1 signaling reporter, we reveal that abluminal polarization shields S1P1 from circulating endogenous and synthetic ligands after maturation of the blood-neural barrier, restricting homeostatic signaling to a subset of arteriolar endothelial cells. S1P1 signaling sustains hallmark endothelial functions in the naive brain and expands during ischemia by engagement of cell-autonomous S1P provision. Disrupting this pathway by endothelial cell-selective deficiency in S1P production, export, or the S1P1 receptor substantially exacerbates brain injury in permanent and transient models of ischemic stroke. By contrast, profound lymphopenia induced by loss of lymphocyte S1P1 provides modest protection only in the context of reperfusion. In the ischemic brain, endothelial cell S1P1 supports blood-brain barrier function, microvascular patency, and the rerouting of blood to hypoperfused brain tissue through collateral anastomoses. Boosting these functions by supplemental pharmacological engagement of the endothelial receptor pool with a blood-brain barrier penetrating S1P1-selective agonist can further reduce cortical infarct expansion in a therapeutically relevant time frame and independent of reperfusion.Conclusions:This study provides genetic evidence to support a pivotal role for the endothelium in maintaining perfusion and microvascular patency in the ischemic penumbra that is coordinated by S1P signaling and can be harnessed for neuroprotection with blood-brain barrier-penetrating S1P1 agonists.
3. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro
E H Wong, R Clark, E Leung, D Loury, D W Bonhaus, L Jakeman, H Parnes, R L Whiting, R M Eglen Br J Pharmacol. 1995 Feb;114(4):851-9.doi: 10.1111/j.1476-5381.1995.tb13282.x.
1. A series of isoquinolines have been identified as 5-HT3 receptor antagonists. One of these, RS 25259-197 [(3aS)-2-[(S)-1-azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro- 1- oxo-1H-benzo[de]isoquinoline-hydrochloride], has two chiral centres. The remaining three enantiomers are denoted as RS 25259-198 (R,R), RS 25233-197 (S,R) and RS 25233-198 (R,S). 2. At 5-HT3 receptors mediating contraction of guinea-pig isolated ileum, RS 25259-197 antagonized contractile responses to 5-HT in an unsurmountable fashion and the apparent affinity (pKB), estimated at 10 nM, was 8.8 +/- 0.2. In this tissue, the -log KB values for the other three enantiomers were 6.7 +/- 0.3 (R,R), 6.7 +/- 0.1 (S,R) and 7.4 +/- 0.1 (R,S), respectively. The apparent affinities of RS 25259-197 and RS 25259-198, RS 25233-197 and RS 25233-198 at 5-HT3 receptors in membranes from NG-108-15 cells were evaluated by a [3H]-quipazine binding assay. The -log Ki values were 10.5 +/- 0.2, 8.4 +/- 0.1, 8.6 +/- 0.1 and 9.5 +/- 0.1, respectively, with Hill coefficients not significantly different from unity. Thus, at these 5-HT3 receptors, the rank order of apparent affinities was (S,S) > (R,S) > (S,R) = (R,R). 3. RS 25259-197 displaced the binding of the selective 5-HT3 receptor ligand, [3H]-RS 42358-197, in membranes from NG-108-15 cells, rat cerebral cortex, rabbit ileal myenteric plexus and guinea-pig ileal myenteric plexus, with affinity (pKi) values of 10.1 +/- 0.1, 10.2 +/- 0.1, 10.1 +/- 0.1 and 8.3 +/- 0.2, respectively. In contrast, it exhibited low affinity (pKi granisetron> (S)-zacopride> tropisetron> (R)-zacopride> ondansetron> MDL 72222.5. In contrast to the majority of radioligands available to label 5-HT3 receptors, [3H]-RS 25259-197 labelled a high affinity site in hippocampus from human post-mortem tissue with an equilibrium dissociation constant (Kd) of 0.15 +/- 0.07 nM and density (BmaX) of 6.8 +/- 2.4 fmol mg-1 protein. Competition studies in this tissue indicated a pharmacological specificity consistent with labelling of a 5-HT3receptor.6. Quantitative autoradiographic studies in rat brain indicated a differential distribution of 5-HT3receptor sites by [3H]-RS 25259-197. High densities of sites were seen in nuclear tractus solitaris and area postrema, a medium density in spinal trigeminal tract, ventral dentate gyrus and basal medial amygdala,and a low density of sites in hippocampal CAl, parietal cortex, medium raphe and cerebellum.7 In conclusion, the functional, binding and distribution studies undertaken with the radiolabelled and non-radiolabelled RS 25259-197 (S,S enantiomer) established the profile of a highly potent and selective5-HT3 receptor antagonist.
Cat No.: BP-100040
Purity: ≥98%
